Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Vi-DT Typhoid Conjugate Vaccine
NCT04051268Phase 3Completed
- Sponsor
- Bio Farma
- Start
- Mar 2020
- Primary completion
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Typhoid conjugate vaccine Vi-DT in typhoid fever, sponsored by Bio Farma. Started Mar 2020; status: completed.
02
Drugs
Typhoid conjugate vaccine Vi-DT
03
Conditions
typhoid fever
Beyond the preview
Go deeper on NCT04051268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04051268.